Search

Your search keyword '"Chien, Amy Jo"' showing total 16 results
Start Over Author "Chien, Amy Jo" Search Limiters Peer Reviewed
16 results on '"Chien, Amy Jo"'

3. Synchronous or metachronous breast and colorectal cancers in younger-than-average-age patients: a case series.

Author

Silverstein, Jordyn, Wright, Francis, Stanfield, Dalila, Chien, Amy Jo, Wong, Jasmine M, Park, John W, Blanco, Amie, Loon, Katherine Van, and Atreya, Chloe E

Subjects
BREAST tumor treatment, ACADEMIC medical centers, BREAST tumors, MULTIPLE tumors, DEMOGRAPHIC characteristics, DISEASE management, COLORECTAL cancer, RETROSPECTIVE studies, DESCRIPTIVE statistics, CASE studies, GENETIC mutation, INDIVIDUALIZED medicine, HEALTH care teams, ADULTS
Abstract

Background The incidence of breast and colorectal cancer (CRC) in younger-than-average-age patients is rising and poorly understood. This is the largest study on patients with both cancers who are less than 60 years old and aims to characterize demographic, clinicopathologic, and genetic features and describe therapeutic dilemmas and management strategies. Materials and Methods This is a retrospective medical records review of patients at the University of California San Francisco with both primary breast and CRC before age 60. Results Fifty-one patients were identified; 41 had detailed medical records. Median age of diagnosis with breast cancer was 43 (range 27-59) and CRC was 50 (28-59). Most were Caucasian (38, 74.5%) and never smokers (23, 56.1%); about half were current alcohol consumers (20, 48.8%) and about one-third had sedentary jobs (14, 34.1%). Average BMI was 25.8 (range: 14-49), and 30% were overweight or obese. Breast was the first cancer diagnosed in 36 patients (70.6%) and 44 (86.3%) had a metachronous CRC diagnosis. Breast cancer was early stage (0-2) in 32 (78.0%) patients whereas CRC was split between early stage (1-2) in 14 (34.1%) and later stage (3-4) in 19 (46.2%). Ten patients (24.3%) had a known germline mutation, although 23 (56.1%) had a family history of cancer in a first-degree relative. Conclusion Younger patients with both breast and CRC are a unique cohort, often without known risk factors. Alcohol consumption and sedentary jobs were the most common risk factors, and about one-quarter had a known genetic predisposition. Comanagement of both cancers requires individualized, multidisciplinary care. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

4. Rates of pathologic complete response (pCR)after neoadjuvant datopotamab deruxtecan (Dato): Results from the I-SPY2.2 trial.

Author

Meisel, Jane Lowe, Khoury, Katia, Chien, Amy Jo, Wallace, Anne M., Arora, Mili, Rozenblit, Mariya, Williams, Nicole Olivia, Nanda, Rita, Borges, Virginia F., Stringer-Reasor, Erica Michelle, Boughey, Judy Caroline, Nangia, Chaitali, Vaklavas, Christos, van 't Veer, Laura, DeMichele, Angela, Hylton, Nola, Yee, Douglas, Yau, Christina, and Esserman, Laura

Published
2024
Full Text
View/download PDF

8. Oral paclitaxel and dostarlimab with or without trastuzumab in early-stage, high-risk breast cancer: Results from the neoadjuvant ISPY 2 TRIAL.

Author

Shatsky, Rebecca Arielle, Thomas, Alexandra, Yau, Christina, Chien, Amy Jo, Falkson, Carla Isadora, Stringer-Reasor, Erica Michelle, Omene, Coral Oghenerukevwe, Trivedi, Meghna S., Boughey, Judy Caroline, Sanford, Amy, Arora, Mili, Sanft, Tara B., Nanda, Rita, Isaacs, Claudine, Brown, Thelma, Hylton, Nola, DeMichele, Angela, Yee, Douglas, and Esserman, Laura

Published
2023
Full Text
View/download PDF

9. Oral paclitaxel, carboplatin, and dostarlimab (OPE/Cb/D) without and with trastuzumab in early-stage, high-risk breast cancer: Results from the neoadjuvant I-SPY 2 TRIAL.

Author

Yeung, Kay T, Kalinsky, Kevin, Yau, Christina, Chien, Amy Jo, Boughey, Judy Caroline, Stringer-Reasor, Erica Michelle, Falkson, Carla Isadora, Albain, Kathy S., Mayer, Ingrid A., Trivedi, Meghna S., Nanda, Rita, Douglas, Emily H., Omene, Coral Oghenerukevwe, Rugo, Hope S., Isaacs, Claudine, Parker, Beverly, DeMichele, Angela, Yee, Douglas, and Esserman, Laura

Published
2023
Full Text
View/download PDF

12. Phase Ib study of talimogene laherparepvec (T-VEC) in combination with chemotherapy (CT) or endocrine therapy (ET) in patients with metastatic, unresectable, or locoregionally recurrent HER2-negative breast cancer (BC).

Author

Huppert, Laura Ann, Gliwa, Amelia S, Tait, Madeline, Quintal, Laura, Starzinski, Stephanie, Cheung, Alexander, Moasser, Mark M., Majure, Melanie, Melisko, Michelle E., Rugo, Hope S., Munster, Pamela N., Campbell, Michael J., Fong, Lawrence, and Chien, Amy Jo

Published
2023
Full Text
View/download PDF

13. Biomarkers predicting response to 5 immunotherapy arms in the neoadjuvant I-SPY2 trial for early-stage breast cancer (BC): Evaluation of immune subtyping in the response predictive subtypes (RPS).

Author

Wolf, Denise M., Yau, Christina, Campbell, Michael J., Glas, Annuska M., Mittempergher, Lorenza, Kuilman, Midas M., Barcaru, Andrei, Brown Swigart, Lamorna, Nanda, Rita, Chien, Amy Jo, Pusztai, Lajos, Stringer-Reasor, Erica Michelle, Shatsky, Rebecca Arielle, Isaacs, Claudine, Perlmutter, Jane, DeMichele, Angela, Yee, Douglas, Esserman, Laura, and van 't Veer, Laura

Published
2023
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results